“Rich is an experienced, well-respected industry leader with an impressive medical, clinical development and regulatory background from his tenure at PhRMA, the U.S.
Akcea is preparing for the approval and launch of TEGSEDI™ (inotersen) for the treatment of hereditary transthyretin amyloidosis (hATTR) and WAYLIVRA™ (volanesorsen) for the treatment of familial chylomicronemia syndrome, or FCS. Both drugs are under regulatory review in the US, EU and
“Akcea’s accomplishments are significant with two products for devastating rare diseases approaching potential approvals worldwide and an innovative late stage pipeline advancing. This is a testament to the expertise of the leadership team and Board steering the Company,” said Dr. Moscicki. “I look forward to contributing to the guidance and governance of the Company and offering my expertise in the important months ahead as Akcea transitions into a commercial rare disease company.”
Dr. Moscicki has been the Executive Vice President for Science and Regulatory Advocacy and the Chief Medical Officer at
This press release includes forward-looking statements regarding the business of Akcea Therapeutics, Inc. and the therapeutic and commercial potential of TEGSEDI (inotersen), WAYLIVRA (volanesorsen) and other products in development. Any statement describing Akcea’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Akcea’s forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Akcea’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Akcea. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Akcea's programs are described in additional detail in Akcea's most recent quarterly report on Form 10-Q and most recent annual report on Form 10-K on file with the SEC. Copies of these and other documents are available from the Company.
In this press release, unless the context requires otherwise, “Ionis”, “Akcea,” “Company,” “Companies,” “we,” “our,” and “us” refers to Ionis Pharmaceuticals and/or Akcea Therapeutics.
Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics™, TEGSEDITM and WAYLIVRATM are trademarks of Akcea Therapeutics, Inc.
Investor and Media Contact:
Head of Communications, Akcea Therapeutics
T: +1 617 207 8509